New progress in research and application of fenneridone
10.12092/j.issn.1009-2501.2022.04.016
- Author:
Kuan CHENG
1
Author Information
1. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases
- Publication Type:Journal Article
- Keywords:
Aldosterone;
Eplerenone;
Finerenone;
Mineralocorticoid receptor antagonist;
Spironolactone
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(4):450-456
- CountryChina
- Language:Chinese
-
Abstract:
Aldosterone is a mineralocorticoid hormone produced by the adrenal cortex, which acts on receptors in the distal and collecting tubules of the nephron, causing reabsorption of sodium and secretion of potassium. Aldosterone can promote inflammatory response and lead to myocardial remodeling and fibrosis. Aldosterone acts through mineralocorticoid receptor (MR), which is mainly expressed in heart, kidney and blood vessels. Excessive activation of MR can cause endothelial dysfunction, fibrinolysis disorder, oxidative stress, cardiovascular and renal fibrosis, and eventually lead to organ injury, dysfunction and even organ failure. Mineralocorticoid receptor antagonist (MRA) can achieve cardiorenal protection by inhibiting inflammation and fibrosis caused by MR activation. The novel nonsteroidal MRA fenneridone can effectively block MR with its high selectivity and bring definite cardiac and renal protective effects.
